Andrew Powaleny is Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.
Recent Posts
Leading researchers to spotlight the critical role of biopharmaceutical R&D
By Andrew Powaleny | October 1, 2020
Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world.
Read More
Summer reading in the age of COVID-19
By Andrew Powaleny | August 21, 2020
As the summer of 2020 starts to creep to a close, America’s biopharmaceutical research companies are working around the clock to identify new treatments to reduce COVID-19 infection and vaccines,...
Read More
The patient perspective navigating COVID-19
By Andrew Powaleny | August 11, 2020
As PhRMA members work around the clock to combat COVID-19, the pandemic has had a tremendous impact around the globe. But for those patients who are currently impacted by a health care condition,...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
By Andrew Powaleny | August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
By Andrew Powaleny | July 21, 2020
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing...
Read More
What scientific experts are saying about vaccine safety
By Andrew Powaleny | June 4, 2020
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...
Read More
New report shows nearly 260 vaccines in development, including dozens for COVID-19
By Andrew Powaleny | April 23, 2020
Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most...
Read More
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
By Andrew Powaleny | April 6, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for...
Read More
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
By Andrew Powaleny | March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...
Read More
Nearly 400 cell and gene therapies in development to target a broad range of diseases
By Andrew Powaleny | March 10, 2020
In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
